The most common mechanism of resistance to quinolones in E coli is mutation in the genes that encode the subunits of the quinolone target topoisomerases, specifically DNA gyrase (topoisomerase II, in gyrA), and topoisomerase IV (in parC). 9, 10 These mutations are located in the QRDR of gyrA and its homologous region of parC. 10, 11 Mutations in gyrB and parE are less important and rarely contribute to quinolone resistance. 12 Double mutations in gyrA are generally required for high-level resistance, 13, 14 whereas mutations in parC are less frequent and are associated with lower-level resistance. 9, 11 In addition to mutations in the QRDR, resistance to quinolones is now known to be mediated by transferable resistance genes (qnrA, B, C, and S), enzymatic modification (aac [6' ]-Ib-cr), or specific efflux pumps (qepA). [15] [16] [17] Although these mechanisms confer only low-level resistance, their presence enhances the frequency of selection of chromosomal mutants upon exposure to fluoroquinolones. [15] [16] [17] Although a common cause of fluoroquinolone resistance, mutations in gyrA and parC will not directly cause MDR. Mechanisms of resistance that involve other classes of antimicrobials must be involved in the emergence of MDR. Among the other mechanisms by which gram-negative bacteria become resistant to fluoroquinolone is decreased intracellular drug concentration caused by increased efflux pump activities. 9, 12 Among the different efflux transport proteins, the AcrAB-TolC system is the most active in E coli. This system belongs to the RND family of transporters. This system transports a broad range of substrates, including drugs, endogenous substrates, and toxins. 18 Among the drug substrates for this system are chloramphenicol, lipophilic β-lactams, fluoroquinolones, tetracycline, rifampin, novobiocin, fusidic acid, and nalidixic acid. 18, 19 It is assumed that the evolutionary role of the MDR efflux pump is to protect bacteria against hostile environments (ie, through the transport of harmful substances out of the bacterial cell). Enteric pathogens (eg, E coli) constitutively express efflux pump activities that enable them to survive in environments rich in bile salts and fatty acids, which are substrates for E coli AcrAB-TolC. 20 However, overexpression of the AcrAB-TolC system in E coli is insufficient to cause resistance to ciprofloxacin, chloramphenicol, tetracycline, and cotrimoxazole. 18, 19 It is the combination of a mutation in the QRDR genes with overexpression of an efflux pump that gives rise to high-level resistance to fluoroquinolones. 21 Thus, the induction of AcrAB-TolC efflux pump by efflux pump substrate, such as fluoroquinolones, can cause an increase in resistance to fluoroquinolones and the emergence of MDR phenotypes. 22 The increase of pump expression in the presence of mutations in the QRDR probably explains the high-level resistance associated with MDR.
The AcrAB-TolC efflux pump can be inhibited by a variety of substrates. Efflux pump inhibitors may enhance the activity of some antimicrobials, particularly for gram-negative bacteria, including the Enterobacteriaceae. 10 Among the inhibitors of the AcrAB-TolC system, EPI PAβN reduces resistance caused by the RND efflux systems and can reverse the resistance for antimicrobials that are substrate of the AcrAB-TolC efflux pump.
The association of fluoroquinolone and MDR is generally not addressed in veterinary medicine, especially in companion animals. 3, 4, 8, 23 Studies 9,12 addressing these mechanisms have been largely limited to human strains or isolates of public health concern, such as those collected from food animals. The purpose of the study reported here was to investigate the contribution of gyrA mutation and efflux pumps to fluoroquinolone resistance and MDR among E coli isolates from dogs and cats. 24 Multidrug resistance was defined as resistance to 2 or more drug classes (the class of β lactams included 3 subgroups: penicillins, cephalosporins, and carbapenems [ie, first, second, and third generations]). For each antimicrobial class, MIC ranges were determined by use of the custom-made microdilution plates.
Materials and Methods

Bacterial isolates and culture conditions-Canine
In preliminary studies, EPI g was prepared in 11 mL of Mueller-Hinton broth, then added into custom-made microdilution plates, such that the final concentrations were 10, 25, 50, 100, and 120 mg/L. Inhibition at 100 mg of PAβN/L did not reduce bacterial counts, compared with untreated cultures; accordingly, this concentration of the EPI was used for further studies of the effect of the EPI on overexpression phenotypes among the clinical isolates. Fifty-six clinical E coli isolates were randomly selected such that wide ranges of enrofloxacin MICs were represented. This would allow characterization of the roles of mutation and pump overexpression in fluoroquinolone resistance. Most (43/56) of these clinical isolates had MDR, and 19 fully susceptible isolates were also included. Mutations were determined by use of FRET-PCR assay, 25 and pump overexpression was studied by use of EPI. On the basis of MICs and Clinical and Laboratory Standards Institute guidelines, 24 E coli isolates were designated as susceptible (n = 19), intermediate (4), or resistant (33) .
An efflux pump-overexpressed phenotype was considered present for any isolate for which the MIC for enrofloxacin decreased at least by a factor of 4 (2 tube dilutions) when the MIC was determined in media containing EPI, compared with media not containing EPI. In addition to enrofloxacin, the impact of EPI on changes in MIC was determined for 13 other drugs.
Detection of gyrA gene mutations via FRET-PCR assay-Bacterial DNA for PCR assay was extracted by use of a DNA extraction kit h following the manufacturer' s instructions. The forward and reverse primers and probes designed specifically for gyrA are listed (Appendix 2). The length of the amplified product was 310 bp. The copy number of E coli gyrA was determined by use of real-time PCR assay in a real-time PCR system.
25,i
The primers and probes were designed by use of statistical software.
j The execution protocols for stringent PCR assay and melting curve analysis were optimized.
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Statistical analysis-The MICs for 50% and 90% of isolates were calculated for each drug and for all 56 isolates subjected to EPI. Furthermore, a cumulative percentage of susceptibility was calculated by use of epidemiological software k and was used to compare the MIC of isolates before and after EPI. The odds ratio of resistance in isolates resistant to fluoroquinolone versus isolates susceptible to fluoroquinolone but resistant to other antimicrobial agents associated with single-drug resistance versus MDR was determined. The frequency of resistance to specific antimicrobials in isolates with MDR phenotypes that are resistant to enrofloxacin was investigated. Analyses were performed by use of statistical software.
l For all comparisons, a value of P < 0.05 was considered significant.
Results
Fluoroquinolone susceptibility patterns-Seventy-one percent (381/536) of the isolates had resistance to 1 or more drugs. Of the 381 isolates expressing a resistant phenotype, 19% (n = 72) included fluoroquinolone resistance. The expression of MDR was greater in isolates with resistance to fluoroquinolones (98.6%), compared with those without resistance to fluoroquinolones (32%; odds ratio, 158.4 [95% confidence interval, 27.3 to 915.4]; Table 1 ). Regarding association of resistance among antimicrobials, isolates resistant to fluoroquinolone were most frequently associated with resistance to β-lactams (89%), followed by doxycycline (72%), gentamicin (41%), chloramphenicol (34%), and trimethoprim-sulfamethoxazole (32%; Figure 1 ).
Target mutations in gyrA-Among susceptible isolates (n = 19), most (17) had no gyrA mutation in the tested region. However, 2 susceptible isolates with MICs of 0.25 and 0.5 mg/L, respectively, each had a single mutation (ie, S83L and D87G). For intermediate isolates (n = 4; MIC = 1 to 2 mg/L), all isolates had a single gyrA mutation (S83L). All resistant isolates (n = 33; MIC ≥ 4 mg/L) expressed either single or double mutations in gyrA (ie, S83L, D87N, or both; Tables 2  and 3 ).
Effect of the EPI PAβN-Inhibition of the efflux pump resulted in a reduction in the MIC to less than the susceptible breakpoint (0.5 mg/L) for isolates with an MIC of ≤ 4 mg/L, regardless of the presence of a mutation. Further, EPI decreased the MIC of enrofloxacin in isolates not associated with MDR (Table 2) . For those isolates with 2 mutations, EPI resulted in a median decrease in MIC by a factor of 16 ( Figure 2 ) and a factor ≥ 32 for isolates with a single mutation. However, the EPI was not able to return isolates with double mutations to a susceptible designation; the median enrofloxacin MIC for those isolates was 4 mg/L. *Each of the following represents a unique class for the purpose of study analysis: enrofloxacin; ampicillin, amoxicillinclavulanic acid, cephalothin, cefoxitin, cefpodoxime, cefotaxime, ceftazidime, meropenem, and ticarcillin-clavulanic acid; doxycycline; chloramphenicol; gentamicin; and trimethoprimsulfamethoxazole.
FQ-R = Fluoroquinolone-resistant isolates. Non FQ-R = Fluoroquinolone-susceptible isolates resistant to other antimicrobials. See Table 2 for key. ≤ 0.06 mg/L, which was less than the susceptible breakpoint. However, in terms of magnitude of decrease in MIC, EPI had the greatest impact on enrofloxacin MICs (MIC decrease factor, ≥ 8 to > 67) for the isolates with single mutations in gyrA (eg, D87G or S83L; MIC ranging from 0.5 to 4 mg/L; Table 2 ). Treatment with EPI also influenced the susceptibility to other selected antimicrobials, including azithromycin, doxycycline, and chloramphenicol. On the basis of changes in the cumulative susceptibility of azithromycin, the percentages of isolates with MICs less than the susceptible and resistant breakpoints were 0% and 46% in the presence of active pumps, respectively, compared with 68% and 96% in the presence of the EPI (Figure 3) . For doxycycline, the cumulative percentages of susceptible isolates with MICs less than the susceptible and resistant breakpoints were 32% and 57% prior to treatment, respectively, and 98% and 98% after treatment with the EPI. For chloramphenicol, 57% and 71% of the isolates were susceptible without EPI, respectively, compared with 84% and 93% susceptible with EPI.
The presence of EPI had no impact on the susceptibility of the isolates to gentamicin.
Discussion
Resistance to fluoroquinolones has increased since their approval in the late 1980s, particularly in the last decade for pathogenic E coli and other gram-negative bacteria. [3] [4] [5] This resistance limits therapeutic options, may lead to therapeutic failure, appears to be associated with MDR, and is expected to become more prevalent in many veterinary hospitals and clinics. 8 Several surveillance studies have tracked changes in E coli susceptibilities to fluoroquinolone and other drug classes over time in humans, but few studies 3, 23 have evaluated the mechanisms that account for this increase in resistance in companion animals. The present study evaluated certain mechanisms of resistance among clinical isolates of E coli. Most fluoroquinolone-resistant isolates had double mutations in gyrA, resulting in a high level (greater than 4 times the resistant breakpoint) of resitance, whereas intermediate to low levels of resistance were found to be associated with a single mutation, which is a finding consistent with previous reports. 14, 26 In our study, approximately 82% (9/11) of isolates expressed low MICs (ie, 0.23 to 0.5 mg/L) toward enrofloxacin and had no mutations in gyrA. This result indicates that mechanisms other than mutations are important for fluoroquinolone resistance, particularly in isolates lacking gyrA mutations. This can be attributed to other resistant determinants such as mutations in regulatory genes and their effect on the constitutive overexpression of efflux pump (ie, AcrAB-TolC system) and porins 18 or PMQR. [15] [16] [17] This can be explored further in the future by investigating the contribution of these mechanisms in resistant isolates.
The present study screened for the efficacy of EPI (ie, PAβN) to decrease MICs toward enrofloxacin and other drugs on the basis of its ability to potentiate levofloxacin activity. 18, 27 The EPI at low concentration (ie, 25 mg/L) did not effectively decrease MICs to enrofloxacin in E coli (data not shown). For enrofloxacin, reduction in the MICs of at least a factor of 4 was observed in almost all of the isolates, with exception of 1 isolate that had an MIC of 0.12 mg/L. These results highlight the importance of basal low-level resistance of gram-negative bacteria to many antimicrobials attributable to a constitutive expression of the efflux pump alone or together with decreased porin expression 9, 12, 18 The concept of MPC, which is defined as the lowest concentration of antimicrobial to inhibit the emergence of mutants from 10 10 CFUs, 28 is considered important in preventing the emergence of antimicrobial resistance. This can be of clinical importance especially for isolates that originally did not have mutations in gyrA and had low MICs (enrofloxacin MICs of 0.06 mg/L). It is possible that those isolates in vivo could develop high MPC through selection of strains with high-level resistance conferred by mutations in gyrA that enable them to survive initially in the higher concentration of fluoroquinolones. In 1 study, 29 one of the MDR mutants of Salmonella enterica serovar Typhimurium (no mutation in gyrA) had high MPC:MIC ratios and had low MICs to both ciprofloxacin and enrofloxacin. Further work is needed to determine MPCs of fluoroquinolones in vitro for those isolates and efficacy of different administration regimens in vivo.
Efflux pump inhibitor decreased the MICs for those isolates with a single mutation in gyrA, in which the MIC of enrofloxacin decreased from intermediate resistance to susceptible. Interestingly, EPI failed to reduce the MICs for enrofloxacin to less than the susceptible breakpoint (ie, 0.5 mg/L) in the presence of double substitutions in gyrA. The presence of an active efflux pump can contribute to further increasing resistance (≥ 8 times) in the presence of a double mutation in gyrA.
Although the magnitude in MIC decrease was greatest for isolates with a single mutation, the greatest change in absolute MIC was for isolates with double mutations. For such isolates, EPI reduced from highlevel resistance to low-level resistance and from lowlevel resistance to intermediate resistance. The greatest change in the MIC concentration was 124 mg/L (from 128 to 4 mg/L; Table 2 ). The therapeutic implication is that for some of these isolates, target MIC can be reached with higher doses. Therefore, it appears that overexpression of the efflux pump alone can have an impact on intracellular drug concentrations, greatly decreasing the concentration such that overexpression of the pump alone could be sufficient to cause resistance to fluoroquinolone and MDR in E coli. Evidence to support this result has been documented with E coli in which inactivation of the acrAB rendered all strains, including those with target gene mutations, hypersusceptible to fluoroquinolones and other drugs. 30 Similar findings have been reported with other organisms, such as Pseudomonas aeruginosa, with deletion of the MexAB-OprM efflux pump 31 ; Salmonella Typhimurium DT204, with inactivation of acrB 32 ; and Campylobacter jejuni, with cmeB deletion. 33 The present study also determined that EPI reduced the MICs of several antimicrobial drugs; PAβN appeared to have the strongest inhibitory effect on macrolides (ie, azithromycin), drugs not normally considered effective against gram-negative organisms. The EPI also appeared to have no effect on the MIC of an aminoglycoside (ie, gentamicin). This was not surprising because the AcrAB-TolC efflux system in E coli has no effect on aminoglycosides, 18 compared with the other efflux system (ie, AcrD), which does affect the efflux of aminoglycosides. 34, 35 Furthermore, the EPI did not decrease the MICs of any β-lactams studied. It may be important to note that the PAβN inhibits efflux of some but not all the substrates of RND pumps, including AcrAB-TolC, because the inhibitor-binding site is substrate specific. 36 Both target gene modification and efflux pumpmediated resistance are underestimated mechanisms by which resistance is mediated in clinical isolates of E coli from dogs and cats. A double mutation in gyrA was proven to be a major mechanism that contributes substantially to emergence of high-level resistance to fluoroquinolone. A single target-based mutation provided only an intermediate level of resistance to enrofloxacin. Inhibition by EPI of the efflux pump, presumably the AcrAB efflux pump, would substantially affect the MICs for fluoroquinolone and other drug classes. Thus, an alternative treatment could be used to target the efflux system to prevent the emergence of fluoroquinolone-resistant and MDR isolates of E coli. 
